Alkem maintains its #1 position in anti-infectives and has strong presence in gastrointestinal, pain management, vitamins, minerals, and nutrients segments while expanding in chronic therapies like neurology, cardiology, and diabetology. The company is positioned for sustained outperformance through accelerating margin expansion, product leadership in domestic therapies, and strategic R&D investments supporting biopharma and complex generic growth.
Cyborg Score Rationale
With a market capitalization of $7.59B and trailing 12-month revenue of $1.6B, Alkem demonstrates solid financial scale. Recent Q3 revenue grew 10.7% to ₹3,737 crore YoY with strategic expansion including a planned acquisition of Occlutech for €180.7M by June 2026, showing growth momentum. However, the company has delivered poor sales growth of 9.21% over the past five years, suggesting execution challenges.
Top Insights
USFDA completed a Pre-Approval Inspection at subsidiary Enzene Biosciences with six procedural observations but none related to data integrity
Alkem declared dividend of ₹43.00 per share for Q3 FY26 with a dividend yield of 0.94%
Following recent shareholder agreement amendment, Alkem holds 88.99% in Enzene Biosciences with Eight Roads at 5.42% and strategic investors F Prime and ERVI at 1.87% and 0.71%
Company maintains #1 position in anti-infectives category in India with expanding chronic therapy portfolio
Named Competitors
Torrent Pharmaceuticals — Leading Indian pharmaceutical competitor
Cipla — Major Indian generic and branded pharmaceutical manufacturer
Mankind Pharma — Indian pharmaceutical company with strong branded generic presence
Marksans Pharma — Indian pharmaceutical manufacturer
Recent Developments
(Feb 2026) Alkem to acquire 51-55% of Occlutech for €180.7M by June 2026
(Feb 2026) Declared interim dividend of ₹43 per share, translating to 0.94% dividend yield
(Feb 2026) Amended Enzene Biosciences' shareholder agreement with F Prime Capital and ERVI investing ₹261.63 crore via private placement, resulting in Alkem holding 88.99% stake
Open the full interactive Alkem Laboratories Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.